少陰人補中益氣湯과 少陰人補中益氣湯加味方의 抗癌效果 및 Cyclophosphamide 에 의한 副作用減少에 미치는 影響 = Effect of Souminbojungikgitang & Souminbojungikgitangkamibang on The Ancancer Activity and The Reduction of Side Effect by Cyclophosphamide

국문 초록 (Abstract)

最近에는 韓藥劑를 利用한 抗癌治療와 化學療法 및 放射線療法의 副作用 減少에 대한 硏究가 活潑히 進行되고 있는 實情이다. 이중 生體의 免疫機能으 增進시키는 것으로 알려진 扶正爲主의 治療法은 西洋醫學에서의 短點을 補完할 수 있어, 本 論文에서는 少陰人 體質의 代表的인 處方중 하나인 少陰人補中益氣湯을 이용하여 少陰人補中益氣湯과 抗癌性이 認定되는 白花蛇舌草와 魚腥草를 加味한 少陰人補中益氣湯加味方의 抗癌效果 및 抗癌劑에 의한 副作用에 減少에 미치는 影響을 探索하여 癌 治療에 도움이 되고자 한다. in vitro에서 B16-Fo과 A549에 대한 細胞毒性效果, B16-Fo과 A549 및 SNU-1에 대한 ED50값, A549에 대한 細胞附着 沮止作用을 觀察하였고, in vitro에서 C57BL/6系와 ICR系에 sarcoma-180을 移植한 후 體重變化, 生命延長율, 腫瘍 미 脾臟의 重量 變化, PFC(plaque forming cell)數, 血液學的 變化, LI-2(interleukin-2)의 生産能 變化 및 FACS에 이한 免疫細胞 變化 등을 觀察하였으며, cyclophosphamide로 副作用을 誘發한 후 脾臟과 肝臟의 重量 및 血液 變化 등을 觀察하였다. in vitro에서 B16-Fo, A549癌株에 대하여 유효한 항종양 효과가 인정되었고, A549癌株에 대한 細胞附着沮止는 SBT-Ⅲdml 10-3g/㎖가장 顯著하였다. S-180에 의한 동물실험에서도 有意性있게 抗腫瘍 效果가 認定되었으며, PFC數, IL-2의 生産能, T cell, B cell수에서도 유의성있는 增加를 나타내었고, Cyclophosphamide의 副作用에 대한 影響에 있어 GOP活性度는 모든 實驗群에서, GPT活性度는 SBT, SBT-Ⅱ 및 SBT-Ⅲ에서, BUN含量은 SBT-Ⅲ에서, creatinine含量은 SBT-Ⅱ와 SBT-Ⅲ에서 有意性있게 減少하였다.

다국어 초록 (Multilingual Abstract)

In order to prove in effects of Souminbojungikgitang(SBT) & Souminbojungikgitangkamibang(SBT-Ⅰ, SBT-Ⅱ and SBT-Ⅲ) on the anticancer activity and the reduction of side effect by cyclophosphsphamide experimentally, the following studies were done.
The results were obtained as follows:
1. The concentration which showed the cytotoxicity against B16-Fo below 55% was 10-3g/㎖ of SBT-Ⅱ and SBT-Ⅲ groups.
2. The concentration which showed the cytotoxicity against A549 below 55% was 10-3g/㎖ of SBT-Ⅰ and SBT-Ⅲ groups.
3. The values of ED50 below 100㎍/㎖ were showing in SBT-Ⅱ and SBT-Ⅲ groups against B16-Fo, in SBT-Ⅰ, and SBT-Ⅲ groups against A549, and in all groups against SNU-1.
4. The inhibitory effect of cell adhesion to A549 was showing in all groups and SBT-Ⅲ was most effective.
5. The change of bodyweight was significant in all groups, the tumor weight was was significantly in SBT-Ⅰ, SBTⅡ and SBT-Ⅲ groups.
6. Survival time was significantly extended in all groups and T/C was 123% in SBT group, 130% in SBT-Ⅰ group, 132% in SBT-Ⅱ group and 141% in SBT-Ⅲ group.
7. The number of PFC was significantly increased in SBT-Ⅰ, SBTⅡ and SBT-Ⅲ groups.
8. The number of platelet in SBT-Ⅰ, SBT-Ⅱ and SBT-Ⅲ groups, and platelet aggregation in SBT-Ⅱ and SBT-Ⅲ on C57BL/6 intraperitoneally with sarcoma-180 and in all groups on ICR subcutaneous with sarcoma 180 were significantly increased.
9. IL-2 were increased in 100% concentration of all groups, in 50% concentration of SBT, SBT-Ⅱ and SBT-Ⅲ groups and 25% concentration of all groups.
10. T cell in all concentration of all groups, B cell in all concentration of SBT-Ⅰ, macrophage in all concentration of SBT, SBT-Ⅱ and SBT-Ⅲ groups were increased.
11. Side effects induced by cyclophosphamide, GOT in all groups, and in SBT, SBT-Ⅱ and SBT-Ⅲ groups, and the amount of BUN in SBT-Ⅲ groups, and creatinine in SBT-Ⅱ and SBT-Ⅲ groups were significantly reduced.
According to the above results, it can be conducted that Souminbojungikgitang and Souminbojungikgitangkamibang have anticancer effects and are effective in reducing side effects induced by cyclophosphamide, SBT-Ⅲ it were more effective, therefore it can be studied applied clinically and had better be more in future.